<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26809443</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-0500</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2016</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>BMC research notes</Title><ISOAbbreviation>BMC Res Notes</ISOAbbreviation></Journal><ArticleTitle>EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge.</ArticleTitle><Pagination><StartPage>42</StartPage><MedlinePgn>42</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">42</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13104-015-1780-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Enterovirus 71 (EV71) is the most common causative pathogens of hand, foot and mouth disease (HFMD) associated with severe neurological complications. There is a great need to develop prophylactic vaccine against EV71 infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">EV71 virus-like particle (VLP) was produced in yeast expression system by the co-expression of four EV71 structural proteins VP1-VP4. Immunization with the recombinant VLPs elicited potent anti-EV71 antibody responses in adult mice and anti-VLP sera were able to neutralize EV71 virus in vitro. Neonatal mice model demonstrated VLP immunization conferred protection to suckling mice against the lethal viral challenge.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Co-expression of four EV71 structural proteins VP1-VP4 in yeast expression systems is an effective method to produce EV71 VLPs. VLP-based vaccine shows great potential to prevent EV71 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaowen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>College of Life Science and Bioengineering, Beijing University of Technology, 100 Pingleyuan, Chaoyang District, Beijing, People's Republic of China. wxw_wen@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Xiangqian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>College of Life Science and Bioengineering, Beijing University of Technology, 100 Pingleyuan, Chaoyang District, Beijing, People's Republic of China. xiaoxq@bjut.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>College of Life Science and Bioengineering, Beijing University of Technology, 100 Pingleyuan, Chaoyang District, Beijing, People's Republic of China. zmxb129@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>College of Life Science and Bioengineering, Beijing University of Technology, 100 Pingleyuan, Chaoyang District, Beijing, People's Republic of China. liuwei1@bjut.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China. panglin306@sina.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Research Center for Life Science, Beihua University, Jilin, People's Republic of China. sunxinbh@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cen</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Virology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, People's Republic of China. shancen@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Burton B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, University of Toronto, 2075 Bayview Avenue, Toronto, M4N 3M5, Canada. byang@sri.utoronto.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yuming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China. hyming@medmail.com.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Wang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>College of Life Science and Bioengineering, Beijing University of Technology, 100 Pingleyuan, Chaoyang District, Beijing, People's Republic of China. shengwang@bjut.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Life Science and Bioengineering, Beijing University of Technology, 100 Pingleyuan, Chaoyang District, Beijing, People's Republic of China. zengyicdc@sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Res Notes</MedlineTA><NlmUniqueID>101462768</NlmUniqueID><ISSNLinking>1756-0500</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C442501">VP1 protein, Foot-and-mouth disease virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C442459">VP2 protein, Foot-and-mouth disease virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C442460">VP3 protein, Foot-and-mouth disease virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26809443</ArticleId><ArticleId IdType="pmc">PMC4724958</ArticleId><ArticleId IdType="doi">10.1186/s13104-015-1780-x</ArticleId><ArticleId IdType="pii">10.1186/s13104-015-1780-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129(3):304&#x2013;309. doi: 10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Pallansch MA. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res. 1995;39(2&#x2013;3):195&#x2013;205. doi: 10.1016/0168-1702(95)00087-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-1702(95)00087-9</ArticleId><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26(15):1855&#x2013;1862. doi: 10.1016/j.vaccine.2008.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuthill T, Groppelli E, Hogle J, Rowlands D: Picornaviruses. In: Johnson JE, editor. Cell Entry by Non-Enveloped Viruses, vol. 343. Berlin Heidelberg: Springer; 2010. p. 43&#x2013;89.</Citation></Reference><Reference><Citation>Chow M, Newman JFE, Filman D, Hogle JM, Rowlands DJ, Brown F. Myristylation of picornavirus capsid protein VP4 and its structural significance. Nature. 1987;327(6122):482&#x2013;486. doi: 10.1038/327482a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/327482a0</ArticleId><ArticleId IdType="pubmed">3035380</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis JK, Bothner B, Smith TJ, Siuzdak G. Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci USA. 1998;95(12):6774&#x2013;6778. doi: 10.1073/pnas.95.12.6774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.12.6774</ArticleId><ArticleId IdType="pmc">PMC22631</ArticleId><ArticleId IdType="pubmed">9618488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19(4):424&#x2013;429. doi: 10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26(1):91&#x2013;107. doi: 10.1111/j.1574-6976.2002.tb00601.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki Y, Taya K, Nakashima K, Ohyama T, Kobayashi JM, Ohkusa Y, Okabe N. Risk factors for severe hand foot and mouth disease. Pediatr Int. 2010;52(2):203&#x2013;207. doi: 10.1111/j.1442-200X.2009.02937.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1442-200X.2009.02937.x</ArticleId><ArticleId IdType="pubmed">19663940</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng M, El Khatib NF, Tu S, Ren P, Xu S, et al. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin Virol. 2012;53(4):285&#x2013;289. doi: 10.1016/j.jcv.2011.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2011.12.025</ArticleId><ArticleId IdType="pubmed">22265829</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, Chow VTK. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis. 2010;14(12):e1076&#x2013;e1081. doi: 10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998&#x2013;2005. Pediatrics. 2007;120(2):e244&#x2013;e252. doi: 10.1542/peds.2006-3331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-3331</ArticleId><ArticleId IdType="pubmed">17671037</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10(11):778&#x2013;790. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SC, Chang HL, Yan TR, Cheng YT, Chen KT. An eight-year study of epidemiologic features of enterovirus 71 infection in taiwan. Am J Trop Med Hyg. 2007;77(1):188&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">17620652</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20(5&#x2013;6):895&#x2013;904. doi: 10.1016/S0264-410X(01)00385-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KHW, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29(26):4362&#x2013;4372. doi: 10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang GH, Luo YJ, Wu XY, Si BY, Lin L, Zhu QY. Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virol J. 2010;7:106. doi: 10.1186/1743-422X-7-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-106</ArticleId><ArticleId IdType="pmc">PMC2887433</ArticleId><ArticleId IdType="pubmed">20500892</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125(1):61&#x2013;68. doi: 10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9(11):1299&#x2013;1306. doi: 10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JN, Wang W, Duo JY, Hao Y, Ma CM, Li WB, Lin SZ, Gao XZ, Liu XL, Xu YF, et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine. 2010;28(46):7444&#x2013;7451. doi: 10.1016/j.vaccine.2010.08.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.080</ArticleId><ArticleId IdType="pubmed">20831911</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwag HL, Kim HJ, Chang DY. The production and immunogenicity of humanpapillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae. J Microbiol. 2012;50(5):813&#x2013;820. doi: 10.1007/s12275-012-2292-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12275-012-2292-1</ArticleId><ArticleId IdType="pubmed">23124750</ArticleId></ArticleIdList></Reference><Reference><Citation>Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Pro-phylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blindplacebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271&#x2013;278. doi: 10.1016/S1470-2045(05)70101-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(05)70101-7</ArticleId><ArticleId IdType="pubmed">15863374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotech. 2007;18(6):537&#x2013;545. doi: 10.1016/j.copbio.2007.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.copbio.2007.10.013</ArticleId><ArticleId IdType="pmc">PMC7126091</ArticleId><ArticleId IdType="pubmed">18083549</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Jiang S, Wang Y. Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice. Biocheml Biophys Res Commun. 2013;430(1):387&#x2013;393. doi: 10.1016/j.bbrc.2012.11.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2012.11.035</ArticleId><ArticleId IdType="pubmed">23159634</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu CH, Chu C, He CC, Lin TY. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect. 2006;8(7):1671&#x2013;1678. doi: 10.1016/j.micinf.2006.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2006.01.021</ArticleId><ArticleId IdType="pubmed">16815726</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, Iwasaki T, Sata T, Wakita T, Shimizu H. An attenuated strain of enterovirus 71 belonging to genotype A showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol. 2007;81(17):9386&#x2013;9395. doi: 10.1128/JVI.02856-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02856-06</ArticleId><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Chen CY, Lin SY, Chung YC, Chiu HY, Chi WK, Lin YL, Chiang BL, Chen WJ, Hu YC. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine. 2010;28(43):6951&#x2013;6957. doi: 10.1016/j.vaccine.2010.08.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.052</ArticleId><ArticleId IdType="pubmed">20797455</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Han JF, Qin CF, Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine. 2013;31(32):3281&#x2013;3287. doi: 10.1016/j.vaccine.2013.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.019</ArticleId><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther. 2007;5:6. doi: 10.1186/1479-0556-5-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-0556-5-6</ArticleId><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Wang J, Liu L, Zhao H, Shi H, Zhang Y, Jiang L, Li Q. Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys. Hum Vaccines. 2010;6(12):1028&#x2013;1037. doi: 10.4161/hv.6.12.12982.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.6.12.12982</ArticleId><ArticleId IdType="pubmed">21150270</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Zhang Y, Wang J, Zhao H, Jiang L, Che Y, Shi H, Li R, Mo Z, Huang T, et al. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One. 2013;8(1):e54451. doi: 10.1371/journal.pone.0054451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0054451</ArticleId><ArticleId IdType="pmc">PMC3553120</ArticleId><ArticleId IdType="pubmed">23372725</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Liu L, Zhao H, Wang J, Liao Y, Zhang X, Na R, Liang Y, Wang L, Li Q. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine. 2011;29(37):6269&#x2013;6275. doi: 10.1016/j.vaccine.2011.06.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.06.044</ArticleId><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, Cai F, Gao Z, McMinn PC. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine. 2011;29(29&#x2013;30):4829&#x2013;4838. doi: 10.1016/j.vaccine.2011.04.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.070</ArticleId><ArticleId IdType="pubmed">21550375</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang JY, Lien SP, Guo MS, Tasi HP, Hsiao KN, et al. Immunological evaluation and comparison of different EV71 vaccine candidates. Clin Dev Immunol. 2012;2012:831282. doi: 10.1155/2012/831282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/831282</ArticleId><ArticleId IdType="pmc">PMC3447357</ArticleId><ArticleId IdType="pubmed">23008736</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, Ku Z, Liu Q, Wang X, Shi J, Zhang Y, Kong L, Cong Y, Huang Z. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J Virol. 2014;88(1):72&#x2013;81. doi: 10.1128/JVI.01848-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01848-13</ArticleId><ArticleId IdType="pmc">PMC3911748</ArticleId><ArticleId IdType="pubmed">24131712</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M, Bai Y, Liu W, Xiao X, Huang Y, Cen S, Chan PK, Sun X, et al. Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses. BMC Microbiol. 2013;10(13):196&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4029445</ArticleId><ArticleId IdType="pubmed">24320792</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, He D, Li Z, Zheng J, Yang L, Yu M, Yu H, Chen Y, Que Y, Shih JW, et al. Protection against lethal&#xa0;enterovirus&#xa0;71&#xa0;challenge in mice by a recombinant vaccine candidate&#xa0;containing a broadly cross-neutralizing&#xa0;epitope within the VP2 EF loop. Theranostics. 2014;4(5):498&#x2013;513. doi: 10.7150/thno.7457.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.7457</ArticleId><ArticleId IdType="pmc">PMC3964443</ArticleId><ArticleId IdType="pubmed">24669278</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushko P, Pumpens P, Grens E. Development of&#xa0;virus-like&#xa0;particle technology from small highly symmetric to large complex virus-like&#xa0;particle structures. Intervirology. 2013;56(3):141&#x2013;165. doi: 10.1159/000346773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000346773</ArticleId><ArticleId IdType="pubmed">23594863</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Huang JH, Lai CW, Sheng HC, Shih SR, Ho MS, Hu YC. Expression, purification and characterization of enterovirus-71&#xa0;virus-like&#xa0;particles. World J Gastroenterol. 2006;12(6):921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066158</ArticleId><ArticleId IdType="pubmed">16521221</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, Wang YC, et al. Purification and characterization of enterovirus 71 viral particles produced from Vero cells grown in a serum-free microcarrier bioreactor system. PLoS One. 2011;6(5):e20005. doi: 10.1371/journal.pone.0020005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020005</ArticleId><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaragoza C, Saura M, Padalko EY, Lopez-Rivera E, Lizarbe TR, Lamas S, Lowenstein CJ. Viral&#xa0;protease&#xa0;cleavage of inhibitor of kappaBalpha triggers host cell&#xa0;apoptosis. Proc Natl Acad Sci USA. 2006;103(50):19051&#x2013;19056. doi: 10.1073/pnas.0606019103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0606019103</ArticleId><ArticleId IdType="pmc">PMC1748175</ArticleId><ArticleId IdType="pubmed">17138672</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco R, Carrasco L, Ventoso I. Cell&#xa0;killing by&#xa0;HIV-1 protease. J Biol Chem. 2003;278(2):1086&#x2013;1093. doi: 10.1074/jbc.M205636200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M205636200</ArticleId><ArticleId IdType="pubmed">12370191</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoke-Fun C, AbuBakar S. Phylogenetic evidence for inter-typic recombination in the emergence of human enterovirus 71 subgenotypes. BMC Microbiol. 2006;6:74. doi: 10.1186/1471-2180-6-74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-6-74</ArticleId><ArticleId IdType="pmc">PMC1569848</ArticleId><ArticleId IdType="pubmed">16939656</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Tan X, Cui A, Mao N, Xu S, Zhu Z, Zhou J, Shi J, Zhao Y, Wang X, et al. Complete genome analysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14 years. PLoS One. 2013;8(2):e56341. doi: 10.1371/journal.pone.0056341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0056341</ArticleId><ArticleId IdType="pmc">PMC3575343</ArticleId><ArticleId IdType="pubmed">23441179</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao CD, Yergolkar P, Shankarappa KS. Antigenic diversity of enteroviruses associated with nonpolio acute flaccid paralysis, India, 2007&#x2013;2009. Emerg Infect Dis. 2012;18:1833&#x2013;1840. doi: 10.3201/eid1811.111457.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1811.111457</ArticleId><ArticleId IdType="pmc">PMC3559176</ArticleId><ArticleId IdType="pubmed">23092622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessaud M, Razafindratsimandresy R, Nougair&#xe8;de A, Joffret ML, Deshpande JM, Dubot-P&#xe9;r&#xe8;s A, et al. Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversity. PLoS One. 2014;9(3):e90624. doi: 10.1371/journal.pone.0090624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0090624</ArticleId><ArticleId IdType="pmc">PMC3944068</ArticleId><ArticleId IdType="pubmed">24598878</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, et al. Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol. 2009;47(11):3653&#x2013;3662. doi: 10.1128/JCM.00630-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00630-09</ArticleId><ArticleId IdType="pmc">PMC2772620</ArticleId><ArticleId IdType="pubmed">19776232</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Cheng T, Zhu F, Li J, Wang Y, Li Y, Gao F, Yang L, Yao X, Shao J, Xia N, Liang Z, Wang J. The cross-neutralizing activity of enterovirus 71 subgenotype C4 vaccines in healthy chinese infants and children. PLoS One. 2013;8(11):e79599. doi: 10.1371/journal.pone.0079599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079599</ArticleId><ArticleId IdType="pmc">PMC3834186</ArticleId><ArticleId IdType="pubmed">24260259</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang JY, Jiang R, Hsieh YC, Tsao A, Wu CL, Huang JL. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One. 2013;8(11):e79783. doi: 10.1371/journal.pone.0079783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079783</ArticleId><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>